



ASX ANNOUNCEMENT

Lumos completes A\$4.75m Placement and launches Share Purchase Plan

CAPITAL RAISE AND COMPANY HIGHLIGHTS:

- Lumos has received firm commitments for approximately A\$4.75 million via an institutional placement at A\$0.07 per share
- The Placement was well supported by a small group of existing institutional shareholders
- The Company will also offer a Share Purchase Plan (SPP) to eligible shareholders to raise up to an additional A\$4.75 million at the same issue price as the Placement
- Funds raised under the Placement and SPP are intended to be used to buyback outstanding convertible notes and to provide general working capital
- US FDA regulatory clearance recently awarded for Lumos' FebriDx® point-of-care test
- Significant operational turnaround in last 12 months including reduction in operating costs
- Strategic partnership with Hologic – development contracts for new and existing products

MELBOURNE, Australia (10 July 2023) – Lumos Diagnostics (ASX: LDX), (**Lumos** or the **Company**) is pleased to announce that it has received firm commitments from institutional investors to raise approximately A\$4.75 million in gross proceeds (**Placement**).

Details to participate in a webinar that will be held at 11:00am on Monday 10 July 2023, during which CEO Doug Ward will discuss the capital raising and provide an update on the Company's activities, are provided at the end of this release.

The Placement will result in the issue of approximately 67.9 million new fully paid ordinary shares at A\$0.07 per share (**Placement Shares**), within the Company's existing placement capacity under ASX Listing Rules 7.1 (33.8 million Placement Shares) and 7.1A (34.1 million Placement Shares). Completion of the Placement is expected to occur on or around 14 July 2023.

The issue price represents an 18.6% discount to the last closing price on 5 July 2023, being the last day the Company traded prior to the Placement, and a 25.7% discount to the 5-day volume weighted average share price on 5 July 2023.

The Company will also offer eligible shareholders, being those holders of shares with an address in Australia or New Zealand as at 7.00pm (AEST) on Friday, 7 July 2023, the opportunity to participate in a Share Purchase Plan (**SPP**). Eligible shareholders will be entitled to apply for up to A\$30,000 of new fully paid ordinary shares at the same issue price as the Placement (A\$0.07 per share) to raise up to an additional A\$4.75 million (before costs).

The Company will apply to ASX for a waiver of Listing Rule 7.1, to permit the Company to offer new shares under the SPP at an issue price of A\$0.07 per new share (**Waiver**). In the event that the Waiver is not granted, the Company intends to seek shareholder approval to issue the new shares under the SPP (along with any shortfall under the SPP (if any)), and the issue of new shares under the SPP would be conditional on receipt of such shareholder approval.

Further details in relation to the SPP, will be provided to eligible shareholders in an SPP offer booklet, which is expected to be made available to eligible shareholders and lodged on ASX on Thursday, 13 July 2023.

Participation in the SPP is optional. Lumos reserves the right (in its absolute discretion) to scale back applications under the SPP if demand exceeds A\$4.75 million.

Proceeds raised under the Placement and SPP are intended to be used to buyback outstanding convertible notes and provide general working capital.

“We are extremely grateful for the strong support we have received from our key Institutional shareholders for this raise, and are delighted to be able to offer our shareholders the ability participate in this next stage of growth for Lumos on the same terms through a Share Purchase Plan,” said Doug Ward, CEO of Lumos Diagnostics. “Lumos is at a very exciting stage right now having just secured an FDA clearance for FebriDx much earlier than expected, while continuing to build a robust pipeline of commercial services projects and partnerships. We have strengthened our strategic relationship with Hologic through new development contacts and a sale-and-leaseback agreement that was announced in March 2023. The funds from this current raise will allow Lumos to strengthen its capital structure, by enabling the Company to buy back outstanding convertible notes, and provide working capital to assist its manufacturing and commercial preparations for the anticipated growth in demand for FebriDx.”

Bell Potter Securities Limited is acting as lead manager and bookrunner to the capital raising.

Key Dates for Capital Raising

Event	Timing (Sydney time)
Record Date for the SPP	7.00pm Friday, 7 July 2023
Capital Raising announced and trading halt lifted	Monday, 10 July 2023
SPP opens	Thursday, 13 July 2023
Settlement of the Placement	Thursday, 13 July 2023
Allotment of new shares under the Placement	Friday, 14 July 2023
SPP closes	Thursday, 27 July 2023
Allotment of new shares under the SPP	Thursday, 3 August 2023

This timetable is indicative only and subject to change. The Company reserves the right to alter the above dates at any time, including amending the period for the SPP offer or accepting late applications, either generally or in particular cases, at its discretion and without notice to you, subject to the ASX Listing Rules, the Corporations Act 2001 (Cth) and any other applicable rules. The commencement of trading and quotation of new shares under the Placement and SPP offer is subject to ASX confirmation.

This announcement was approved by the Lumos Disclosure Committee.

-Ends-

Webinar

Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) is pleased to invite shareholders and other interested parties to a Shareholder Webinar hosted by CEO Doug Ward to discuss the capital raising and provide an update on the Company’s activities.

The webinar will be held on **Monday 10 July 2023 at 11.00am AEST.**

For the Q&A session, investors are invited to send questions prior to the webinar to:
matt@nwrcommunications.com.au

Register for the webinar at the link below:

https://us02web.zoom.us/webinar/register/WN_b75s1DwGR7-Ki7cYrwDWEw

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those who would prefer to join by phone. A recording will be available at the above link shortly after the conclusion of the live session.

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598

Important Notices

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.

Not for Distribution or Release in the United States

This letter does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any person in the United States or in any other jurisdiction in which such an offer would be illegal. The securities have not been, nor will be, registered under the U.S. Securities Act of 1933 as amended (U.S. Securities Act) or under the securities laws of any state or other jurisdiction of the United States. The securities may not be issued to, purchased or traded by, or taken up by, any person in the United States or any person acting for the account or benefit of a person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Important Notice to Nominees

Because of legal restrictions, you must not send copies of this letter nor any material relating to the SPP to any of your clients (or any other person) acting for the account or benefit of any person in any other jurisdiction outside of Australia and New Zealand. Failure to comply with these restrictions may result in violations of applicable securities laws.